Rocket Lab’s Rally Isn’t Random: 3 Catalysts Driving The Stock Higher

Photo of Vandita Jadeja
By Vandita Jadeja Published

Quick Read

  • After dropping 36% from its $151 peak, RKLB's $2.2B backlog and new $266M Space Force contract support a BUY rating with 92% upside.

  • RKLB generates 13x ASTS's quarterly revenue at roughly 2x the market cap, while LUNR's $2.56B valuation reflects its lack of a launch platform.

  • The most widely read finance newsletter on Substack isn't published by a bank, it's Doomberg, where 383,000+ readers get the energy and macro analysis the mainstream press misses. 24/7 Wall St. readers save 17% on their first year here.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Rocket Lab’s Rally Isn’t Random: 3 Catalysts Driving The Stock Higher

© Evgeniyqw / Shutterstock.com

Rocket Lab (NASDAQ: RKLB | RKLB Price Prediction) has been volatile this year. After a sharp July drawdown, our model sees a buying opportunity. Our 24/7 Wall St. price target for Rocket Lab is $124.43, implying 92.38% upside from the current price of $64.68.

We rate the shares a buy with moderate confidence, driven by a Space Force contract cascade, Neutron progress, and a record backlog.

An infographic with a dark blue background, white and green text, predicting Rocket Lab's (RKLB) 12-month stock price. The top section, 'The Call', shows a current price of $64.68 (July 31, 2026) moving to a target price of $124.43, representing a 92.38% upside, with a 'BUY' recommendation and 'Moderate Confidence'. Sections detailing 'How We Got There' and 'Our Adjustments' include a weighted base price of $114.47 and a 247Factor Adjustment of x1.087, with bar charts illustrating contributing factors like analyst consensus, sector momentum, beta volatility, and social sentiment leading to the final target. 'Bull Case' lists factors like Neutron progress and defense wins with a $158.75 price target. 'Bear Case' lists concerns like cash burn and premium valuation with a $97.24 price target. The 'The Bottom Line' reiterates the 'BUY' call with a target of $124.43 (+92.38%).
24/7 Wall St.

24/7 Wall St. Price Target Summary

Metric Value
Current Price $64.68
24/7 Wall St. Price Target $124.43
Upside 92.38%
Recommendation BUY
Confidence Level 50%

A Brutal July Reset After a $151 Peak

Shares are down 36.37% over the past month and 7.59% over the past week, though the stock shows a 39.28% gain over the last year and sits well above its $37.57 52-week low. The pullback from the $151 52-week high reflects sector rotation after SpaceX’s June listing and dilution concerns tied to the pending $8 billion Iridium acquisition.

Fundamentals tell a different story. Q1 FY2026 revenue hit $200.35 million, up 63.5% year over year, with an EPS loss of -$0.07 beating the -$0.0787 consensus. Backlog swelled to $2.2 billion, and on July 21, Rocket Lab landed a $266 million Space Force suborbital launch contract, its largest defense award.

RKLB earnings explorer

Three Catalysts Driving Higher

Bulls cite three drivers. First, Neutron: Rocket Lab completed a full-duration burn test of the second-stage AVac engine in mid-July, keeping the medium-lift reusable rocket on track for a later 2026 debut.

Second, defense wins: Rocket Lab was selected for the Golden Dome Space Based Interceptor program with Raytheon, holds the $816 million SDA Tracking Layer Tranche 3 contract, and now adds the $266 million Space Force award.

Third, Pentagon spending: FY2027 Space Force procurement includes 9 Space Development Agency launches as part of a $59.7 billion space-based systems budget.

Citizens reaffirmed a Market Outperform rating with a $130 target. Stifel’s Erik Rasmussen maintained a Buy at $132. Our bull case scenario points to $158.75 over the next 12 months if Neutron flies successfully and Iridium closes on schedule.

RKLB analyst ratings

Where the Rally Could Stall

The bear case starts with cash burn. FY2025 free cash flow was -$321.8 million, and Q1 alone saw $450 million raised through an ATM offering. Piper Sandler initiated at Neutral with an $83 target citing premium valuation, with the stock trading at a price-to-sales ratio of 54.

Bulls counter that heavy capex reflects Neutron infrastructure and integration of the Mynaric, Motiv, and Geost acquisitions, broadening the addressable market. If Neutron slips or Iridium financing hits snags, our bear case target is $97.24.

RKLB price target

Valuation Against Peers

AST SpaceMobile (NASDAQ: ASTS) is the direct-to-device satellite counterpart. Q1 2026 revenue was just $14.73 million against a $36.58 million consensus and a market cap near $16 billion. Rocket Lab generates more than 13x ASTS’s quarterly revenue at roughly 2x the market cap, making the $124 target reasonable.

Intuitive Machines (NASDAQ: LUNR) is the closest defense-and-services comp. LUNR posted Q1 2026 revenue of $186.73 million at a $2.56 billion market cap. That’s a fraction of Rocket Lab’s multiple, but LUNR lacks a launch platform and Neutron optionality. Against these peers, our target looks fair.

Company Q1 2026 Revenue Market Cap
Rocket Lab $200.35M $36.61B
AST SpaceMobile $14.73M $16.0B
Intuitive Machines $186.73M $2.56B

Rocket Lab Price Projection 2026-2030

Our 24/7 Wall St. price target of $124.43 stands with a buy rating and 50% confidence. The key factor is a record $2.2 billion backlog colliding with a July drawdown that has erased the froth.

The setup rewards investors comfortable with the 2.55 beta who want Neutron optionality. The thesis weakens if another Neutron delay materializes or if the Iridium deal breaks.

RKLB price scenario

Assuming Neutron enters commercial service and defense contract flow continues at current pace:

Year 24/7 Wall St. Price Target
2026 $85.51
2027 $124.43
2028 $177.79
2029 $254.02
2030 $362.94

These projections assume Rocket Lab executes on Neutron cadence, closes Iridium without dilutive surprises, and captures share of the expanding Space Force launch budget. A failed Neutron debut or SDA contract loss would materially compress this trajectory.

Contact [email protected] for any questions or corrections.

Photo of Vandita Jadeja
About the Author Vandita Jadeja →

Vandita Jadeja is a financial copywriter who loves to read and write about stocks. She believes in buying and holding for long term gains. Her knowledge of words and numbers helps her write clear stock analysis. She has contributed to several publications, including the Joy Wallet, Benzinga, The Motley Fool and InvestorPlace.

Continue Reading

Top Gaining Stocks

DE Vol: 1,582,465
NDSN Vol: 537,060
COIN Vol: 10,456,837
CF Vol: 1,522,714
CBOE Vol: 421,170

Top Losing Stocks

MRNA Vol: 55,511,154
WMT Vol: 47,301,608
CTRA Vol: 73,319,495
NCLH Vol: 9,398,454
CRWD Vol: 3,716,070